Patents by Inventor Sven Meuth

Sven Meuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NDP-MSH FOR TREATMENT OF INFLAMMATORY AND/OR NEURODEGENERATIVE DISORDERS OF THE CNS
    Publication number: 20200360484
    Abstract: The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 26, 2020
    Publication date: November 19, 2020
    Inventors: THOMAS LUGER, KARIN LOSER, SVEN MEUTH
  • Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis
    Patent number: 10112982
    Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: October 30, 2018
    Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stöcker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
  • DIAGNOSIS OF A NOVEL AUTOIMMUNE DISEASE
    Publication number: 20180298072
    Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 18, 2018
    Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stöcker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
  • NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES
    Publication number: 20180250308
    Abstract: The present invention provides novel means and methods for treatment auf immunemediated inflammatory diseases.
    Type: Application
    Filed: August 24, 2016
    Publication date: September 6, 2018
    Inventors: Stefan Bittner, Sven Meuth, Bernhard Wunsch, Dirk Schepmann
  • Factor XII inhibitors for the treatment of neurological inflammatory disorders
    Patent number: 9957329
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 1, 2018
    Assignees: CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg, Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
  • DIAGNOSIS OF A NOVEL AUTOIMMUNE DISEASE
    Publication number: 20160311876
    Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.
    Type: Application
    Filed: March 23, 2016
    Publication date: October 27, 2016
    Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stoecker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
  • Factor XII Inhibitors for the Treatment of Neurological Inflammatory Disorders
    Publication number: 20140378653
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Application
    Filed: January 31, 2013
    Publication date: December 25, 2014
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte